Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 14, 2019

SELL
$27.2 - $41.2 $252,416 - $382,336
-9,280 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$19.86 - $32.9 $184,300 - $305,312
9,280 New
9,280 $305,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.54B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Blue Crest Capital Management LTD Portfolio

Follow Blue Crest Capital Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Blue Crest Capital Management LTD with notifications on news.